HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mami Yoshii Selected Research

Neoplasm Micrometastasis

1/2014Clinical impact of the extent of lymph node micrometastasis in undifferentiated-type early gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mami Yoshii Research Topics

Disease

14Stomach Neoplasms (Stomach Cancer)
05/2022 - 04/2011
13Neoplasms (Cancer)
06/2022 - 04/2011
3Esophageal Squamous Cell Carcinoma
06/2022 - 03/2021
3Inflammation (Inflammations)
01/2022 - 06/2020
2Rectal Neoplasms (Rectal Cancer)
12/2021 - 12/2020
2Carcinoma (Carcinomatosis)
11/2021 - 04/2011
2Esophageal Neoplasms (Esophageal Cancer)
10/2021 - 09/2021
2Neoplasm Metastasis (Metastasis)
12/2020 - 11/2014
2Pathologic Constriction (Stenosis)
07/2017 - 11/2014
1Tertiary Lymphoid Structures
01/2022
1Brain Diseases (Brain Disorder)
12/2021
1Pneumonia (Pneumonitis)
10/2021
1Sarcopenia
10/2021
1Anastomotic Leak
09/2021
1Lymphatic Metastasis
12/2020
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
02/2020
1Peptic Esophagitis (Reflux Esophagitis)
07/2017
1Cholangiocarcinoma
11/2014
1Pancytopenia
11/2014
1Jaundice (Icterus)
11/2014
1Ascites
11/2014
1Head and Neck Neoplasms (Head and Neck Cancer)
11/2014
1Neoplasm Micrometastasis
01/2014
1Pancreatic Neoplasms (Pancreatic Cancer)
08/2011
1Adenocarcinoma
08/2011

Drug/Important Bio-Agent (IBA)

4Biomarkers (Surrogate Marker)IBA
05/2022 - 02/2018
3C-Reactive ProteinIBA
01/2022 - 06/2020
3AntigensIBA
02/2018 - 04/2011
2Pharmaceutical PreparationsIBA
06/2022 - 12/2020
2Immune Checkpoint InhibitorsIBA
06/2022 - 09/2020
2Proteins (Proteins, Gene)FDA Link
06/2022 - 04/2011
2Indicators and Reagents (Reagents)IBA
01/2022 - 10/2021
2AlbuminsIBA
09/2021 - 06/2020
2Imatinib Mesylate (Gleevec)FDA Link
03/2021 - 02/2020
2Tumor Biomarkers (Tumor Markers)IBA
12/2020 - 11/2014
2HLA-A Antigens (HLA-A)IBA
05/2013 - 04/2011
2VaccinesIBA
08/2011 - 04/2011
2EpitopesIBA
08/2011 - 04/2011
1NivolumabIBA
01/2022
1Panitumumab (Vectibix)FDA Link
12/2021
1Serum AlbuminIBA
10/2021
1Fluorouracil (Carac)FDA LinkGeneric
03/2021
1Cisplatin (Platino)FDA LinkGeneric
03/2021
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2020
1Keratins (Keratin)IBA
01/2020
1LigandsIBA
12/2019
1CXC ChemokinesIBA
12/2019
1CytokinesIBA
02/2018
1Proton Pump InhibitorsIBA
07/2017
1Histocompatibility Antigens Class IIBA
05/2013
1Antineoplastic Agents (Antineoplastics)IBA
06/2012
1HLA-A*02:01 antigenIBA
08/2011
1Mucin 5ACIBA
08/2011
1Cancer VaccinesIBA
04/2011
1Peptides (Polypeptides)IBA
04/2011

Therapy/Procedure

8Gastrectomy
06/2022 - 07/2017
6Drug Therapy (Chemotherapy)
06/2022 - 11/2014
6Therapeutics
12/2021 - 06/2012
4Immunotherapy
06/2022 - 08/2011
4Neoadjuvant Therapy
06/2022 - 02/2020
4Lymph Node Excision (Lymph Node Dissection)
12/2020 - 01/2014
2Esophagectomy
10/2021 - 09/2021
1Drug Tapering
12/2021
1Adjuvant Chemotherapy
11/2021
1Length of Stay
09/2021
1Splenectomy
12/2020
1Precision Medicine
02/2018
1Stents
11/2014
1Combination Drug Therapy (Combination Chemotherapy)
11/2014